[S-21] Symposium 21 Novel molecular target drugs for MG: How should we use them?

[S-21-4] Economic profile of novel molecular target drugs for MG

^○Jason L. Crowell^1,2 (1.Neurologist, Beth Israel Deaconess Medical Center, 2.Jerome H. Grossman M.D. Graduate Fellow, Harvard Kennedy School)

Dr. Jason Crowell is a Jerome H. Grossman Graduate Fellow in Healthcare Policy at the Harvard Kennedy School and a neurologist at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He completed his residency training at the University of Virginia, where he served as chief resident, followed by a 2-year clinical fellowship in movement disorders at the University of Alabama-Birmingham. In 2020, he completed an internship at the Institute for Clinical and Economic Review, a Boston-based nonprofit organization performing cost-effectiveness analyses of prescription drugs and other health technologies. Dr. Crowell has published on prescription drug pricing in Continuum and Muscle & Nerve and recently spoke on the topic at the American Academy of Neurology's 2020 Fall Conference.